Financial health
- Operating income covered interest expense -15.5× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
GOSS Financials Gossamer Bio, Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $48M | -$170M | 0.0% | -352.2% | -$171M | — | $38M |
| 2024 | $115M | -$57M | 0.0% | -52.2% | -$3M | $0 | $46M |
| 2023 | $0 | -$180M | — | — | -$159M | $12M | $32M |
| 2022 | $0 | -$229M | — | — | -$187M | $24M | $112M |
| 2021 | — | -$234M | — | — | -$190M | $29M | $183M |
| 2020 | — | -$243M | — | — | -$178M | $29M | $486M |
| 2019 | — | -$180M | — | — | -$148M | $28M | $135M |
| 2018 | — | -$147M | — | — | -$55M | — | $105M |
| 2017 | — | -$7M | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $17M | -$47M | 0.0% | -264.6% | -$39M | — | $41M |
| Dec '25 | $14M | -$47M | 0.0% | -333.6% | -$48M | — | $38M |
| Sep '25 | $13M | -$48M | 0.0% | -369.4% | -$36M | — | $9M |
| Jun '25 | $11M | -$38M | 0.0% | -337.4% | -$47M | — | $26M |
| Mar '25 | $10M | -$37M | 0.0% | -372.2% | -$40M | — | $29M |
| Dec '24 | $9M | -$33M | 0.0% | -385.2% | -$35M | $0 | $46M |
| Sep '24 | $9M | -$31M | 0.0% | -357.8% | -$32M | $0 | $28M |
| Jun '24 | $96M | $49M | 0.0% | 54.3% | $116M | $0 | $87M |
| Mar '24 | $0 | -$42M | — | — | -$52M | $10M | $39M |
| Dec '23 | $0 | -$48M | — | — | -$33M | $12M | $32M |
| Sep '23 | $0 | -$40M | — | — | -$34M | $15M | $83M |
| Jun '23 | $0 | -$42M | — | — | -$38M | $18M | $37M |
| Mar '23 | — | -$49M | — | — | -$53M | $21M | $65M |
| Dec '22 | — | -$56M | — | — | -$48M | $24M | $112M |
| Sep '22 | — | -$59M | — | — | -$37M | $15M | $153M |
| Jun '22 | — | -$56M | — | — | -$49M | $18M | $94M |
| Mar '22 | — | -$58M | — | — | -$54M | $29M | $139M |
| Dec '21 | — | -$56M | — | — | -$41M | $29M | $183M |
| Sep '21 | — | -$60M | — | — | -$43M | $29M | $213M |
| Jun '21 | — | -$60M | — | — | -$48M | $29M | $342M |
Valuation over time
How the market has priced GOSS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 1.8× (Dec '24) to 0.8× (Jun '26).
P/S
Frequently asked questions
Is GOSS growing its revenue and profit?
See the revenue and net-income charts above for Gossamer Bio, Inc.'s multi-year trend.
How much debt does GOSS have?
As of FY2025, Gossamer Bio, Inc. reported — of total debt against $38M of cash; operating income covered interest expense -15.5×.
What is GOSS's profit margin?
In FY2025, gross margin was —, operating margin -352.2%, and net margin -351.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.